PATENT CLAIM ANALYSIS

Application Number: 16005647
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2019-05
Patent Classification: ["424", "130100"]

Abstract:
The present invention relates to peptides, particularly human monoclonal antibodies, that bind specifically to poly-N-acetyl glucosamine (PNAG), such as  Staphylococcal  PNAG, in acetylated, partially acetylated and/or fully deacetylated form. The invention further provides methods for using these peptides in the diagnosis, prophylaxis and therapy of infections by bacteria that express PNAG such as but not limited to  Staphylococci  and  E. coli.  Some antibodies of the invention enhance opsonophagocytic killing and in vivo protection against bacteria that express PNAG such as but not limited to  Staphylococci  and  E. coli.  Compositions of these peptides, including pharmaceutical compositions, are also provided, as are functionally equivalent variants of such peptides.

Claim (Index 25):
The method of  claim 14 , wherein the subject is at risk of developing an infection by a bacterial strain expressing PNAG.

Metadata:
- Claim Count in Document: 2.0
- Percentile: 94.0
- Lexical Diversity: 1.75362
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['13103532', '13334869', '14548173', '15270461', '13334807']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.907822052490464
- 35 USC 102 Novelty (BERT): 0.6509613252237227
- Combined Prediction Score: 0.8821359797637899
- Mean Citation Score: 805.8130319999997
- Max Citation Score: 806.9848
- Similarity Product: 585.0358126152038

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test